Astellas Pharma (4503) financial statements

+55.8%since 2016
FY2026 revenue
¥2.1T▲ +11.9%
FY2026 net income
¥291.5B▲ +474.5%
FY2026 diluted EPS
¥162.22▲ +474.4%
FY2026 free cash flow
¥502.5B▲ +219.0%

Astellas Pharma income statement

Astellas Pharma income statement
JPY millionsFY2026FY2025FY2024
Period ended31 Mar 202631 Mar 202531 Mar 2024
Revenue2,139,2451,912,3231,603,672
Gross profit1,730,8201,563,1171,311,187
Operating income382,63341,03925,518
Pretax income376,58731,23724,969
Net income291,53550,74717,045
Diluted earnings per share162.2228.249.47

Astellas Pharma balance sheet

Astellas Pharma balance sheet
JPY millionsFY2026FY2025FY2024
Period ended31 Mar 202631 Mar 202531 Mar 2024
Cash and cash equivalents281,605188,372335,687
Total assets3,567,0423,339,5443,569,603
Total liabilities1,736,1581,826,2891,973,615
Total equity1,830,8841,513,2551,595,988
Long-term debt320,000564,893447,738

Astellas Pharma cash flow statement

Astellas Pharma cash flow statement
JPY millionsFY2026FY2025FY2024
Period ended31 Mar 202631 Mar 202531 Mar 2024
Operating cash flow560,188194,512172,475
Capital expenditure-57,723-37,003-38,056
Free cash flow (derived)502,465157,509134,419
Share repurchases-730-6,960-10,735

Half-year highlights

Half-year highlights
JPY millionsH1 FY2027H1 FY2026H1 FY2025H1 FY2024
Period ended30 Sep 202630 Sep 202530 Sep 202430 Sep 2023
Revenue1,270,8611,030,114935,621767,138
Operating income316,556199,37893,71055,156
Net income241,677147,63573,51135,810
Diluted earnings per share134.4782.1740.9119.90
Operating cash flow270,056282,59977,41153,222
Total assets3,527,7823,450,2913,462,2373,547,406

Astellas Pharma major shareholders

Astellas Pharma major shareholders
HolderShare of classSharesFiled
ブラックロック・ジャパン株式会社9.5%172,696,04820 January 2026
三井住友トラスト・アセットマネジメント株式会社6.4%115,516,14019 September 2025
Mitsubishi UFJ Financial Group, Inc.5.0%90,980,7918 May 2025

Astellas Pharma EDINET filings

Astellas Pharma EDINET filings
FiledFormType
6 November 2026Semiannual Securities ReportHalf-year report
2 July 2026Extraordinary ReportCurrent report
16 June 2026Annual Securities ReportAnnual report
27 April 2026Extraordinary ReportCurrent report
6 November 2025Semiannual Securities ReportHalf-year report
2 July 2025Extraordinary ReportCurrent report
16 June 2025Annual Securities ReportAnnual report
4 February 2025Extraordinary ReportCurrent report

Common questions

What was Astellas Pharma's revenue in fiscal 2026?

Astellas Pharma reported ¥2.1 trillion in revenue for fiscal 2026, the year ended 31 March 2026, up 11.9% from fiscal 2025.

What was Astellas Pharma's net income in fiscal 2026?

Astellas Pharma reported net income of ¥291.5 billion for fiscal 2026, the year ended 31 March 2026, up 474.5% from fiscal 2025. Diluted earnings per share were ¥162.22.

What was Astellas Pharma's free cash flow in fiscal 2026?

Astellas Pharma had ¥502.5 billion in free cash flow in fiscal 2026. Operating cash flow was ¥560.2 billion and capital expenditure was ¥57.7 billion.

What were Astellas Pharma's total assets at the end of fiscal 2026?

Astellas Pharma reported total assets of ¥3.6 trillion at the end of fiscal 2026, the year ended 31 March 2026.

How much Astellas Pharma history do I get?

Every account gets the full history, annual and semiannual, with first reported values and as of dates.